About Radionetics
Radionetics is a company based in San Diego (United States) founded in 2021 by R Scott Struther. Radionetics has raised $136.71 million across 4 funding rounds from investors including Crinetics, Frazier Healthcare Partners and Frazier Life Sciences. Radionetics offers products and services including Small Molecule Radiopharmaceuticals and Diagnostic Radiopharmaceuticals. Radionetics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Diego, United States
- Founders R Scott Struther
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$136.71 M (USD)
in 4 rounds
-
Latest Funding Round
$52.5 M (USD), Series A
Jan 03, 2024
-
Investors
Crinetics
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Radionetics
Radionetics offers a comprehensive portfolio of products and services, including Small Molecule Radiopharmaceuticals and Diagnostic Radiopharmaceuticals.
Delivers targeted radiation to tumors via GPCRs for treatment
Maps tumors using radioisotopes for precise patient identification
People of Radionetics
Unlock access to complete
Funding Insights of Radionetics
Radionetics has successfully raised a total of $136.71M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $52.5 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Radionetics
Radionetics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Crinetics, Frazier Healthcare Partners and Frazier Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investment firm focused on novel therapeutics development.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Radionetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Radionetics
Investment portfolio details for Radionetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Radionetics
Detailed financials for Radionetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Radionetics Comparisons
Peer comparison for Radionetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Radionetics
Radionetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Radionetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Radionetics
Complete news archive for Radionetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Radionetics
Radionetics was founded in 2021.
Radionetics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Radionetics is a funded company, having raised a total of $136.71M across 4 funding rounds to date.
Radionetics was founded in 2021 in San Diego, United States, within the biotechnology sector. Peptide-targeted radiotherapeutics are developed by the company, which bind to receptors overexpressed on tumors. These treatments are focused on neuroendocrine tumors and advanced prostate cancer. Operations center on advancing targeted therapies for oncology applications in the radiopharmaceutical field.
Radionetics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Radionetics offers Small Molecule Radiopharmaceuticals and Diagnostic Radiopharmaceuticals.
Radionetics has 6 investors. Key investors include Crinetics, Frazier Healthcare Partners, Frazier Life Sciences, 5AM Ventures, and DCVC.